Table 1.

Summary of selected novel agents in clinical trials.

Agent	Mechanism	Comments
Elacytarabine [1]	Elaidic Ester of Ara-C	Modest remission in advanced disease
CPX-351 [4,5]	Fixed ratio Dauno/Ara-C	High Response Rate
Clofarabine [7–10, 13, 14]	Nucleoside Analogue	Tolerated in older adults
Dot1L inhibitor [24,25]	Histone Methyltransferase	Encouraging Pre-Clinical data
Sorafenib [22,23]	Multi-Kinase Inhibitor	CR with single agent
AC 220 [21]	FLT-3 Inhibitor	CR with single agent
Sirolimus/Everolimus [15–17]	mTOR inhibitor	CR with single agent
Sapacitabine [18]	Nucleoside Analogue	CR with single agent